{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:06:32Z","timestamp":1763003192542,"version":"3.45.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jtct.2022.08.004","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T22:29:07Z","timestamp":1661466547000},"page":"521-522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Land(mark) ahoy: PFS24 in relapsed\/refractory diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"28","author":[{"given":"Matthew","family":"Matasar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.08.004_bib0001","doi-asserted-by":"crossref","unstructured":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma | N Engl J Med. 2022 Jan 27;386(4):351\u2013363","DOI":"10.1056\/NEJMoa2115304"},{"key":"10.1016\/j.jtct.2022.08.004_bib0002","doi-asserted-by":"crossref","unstructured":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma | N Engl J Med. 2022 Feb 17;386(7):640\u2013654.","DOI":"10.1056\/NEJMoa2116133"},{"issue":"10343","key":"10.1016\/j.jtct.2022.08.004_bib0003","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.jtct.2022.08.004_bib0004","doi-asserted-by":"crossref","unstructured":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | N Engl J Med. 2019 Jan 3;380(1):45\u201356","DOI":"10.1056\/NEJMoa1804980"},{"key":"10.1016\/j.jtct.2022.08.004_bib0005","doi-asserted-by":"crossref","unstructured":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data | Blood Adv. 2022. Jan 25;6(2):533\u2013543","DOI":"10.1182\/bloodadvances.2021005794"},{"issue":"7","key":"10.1016\/j.jtct.2022.08.004_bib0006","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"The Lancet Oncology"},{"issue":"6","key":"10.1016\/j.jtct.2022.08.004_bib0007","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"The Lancet Oncology"},{"issue":"9","key":"10.1016\/j.jtct.2022.08.004_bib0008","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jtct.2022.06.015","article-title":"Progression-free survival at 24 months as a landmark after autologous SCT in relapsed or refractory DLBCLl","volume":"28","author":"Tun","year":"2022","journal-title":"Transplantation and Cellular Therapy"},{"issue":"16","key":"10.1016\/j.jtct.2022.08.004_bib0009","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","article-title":"Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma","volume":"125","author":"Sauter","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2022.08.004_bib0010","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/bloodadvances.2021006415","article-title":"Risk profiling of patients with relapsed\/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA","volume":"6","author":"Herrera","year":"2022","journal-title":"Blood Advances"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722015214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722015214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:02:00Z","timestamp":1763002920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722015214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2666636722015214"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.08.004","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Land(mark) ahoy: PFS24 in relapsed\/refractory diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}